A Case of de novo Annular-plaque Type Psoriasis Following Oxford- AstraZeneca COVID-19 Vaccination

Abstract

Background: There have been increasingly reported cases of new-onset or aggravation of pre-existing dermatoses after the implementation of COVID-19 vaccination. Case Presentation: An elderly male presented with multiple annular scaly plaques all over the body two weeks following administration of the first dose of Oxford-AstraZeneca COVID-19 vaccine. The lesions further aggravated after taking the second dose of the vaccine. The clinical and histopathology features were suggestive of annular plaque psoriasis. Conclusion: We report this first case of de novo plaque psoriasis following the Oxford-AstraZeneca COVID-19 vaccine, and it signifies a potential side effect of autoimmune reactivation after COVID vaccination.

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge

“…In total, 49 studies involving 134 patients were included in this review ( Figure 1 ) and are summarized in Table 1 (new-onset psoriasis) [ 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 ] and Table 2 (psoriasis exacerbation) [ 32 , 33 , 34 , 35 , 39 , 45 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 ,…”

“…Several factors can trigger or contribute to a psoriasis exacerbation, including stress, infections, certain medications, changes in weather or climate, hormonal fluctuations, injury or trauma to the skin, and lifestyle factors such as smoking and excessive alcohol consumption. In this scenario, in total, 107 cases (male: 61 (57.0%); female: 46 (43.0%); mean age: 56.5 ± 13.4 years) of a flare-up of psoriasis collected in 29 articles are described and summarized in Table 2 [ 32 , 33 , 34 , 35 , 39 , 45 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 ]. Of these, 74 (69.2%), 12 (11.2%), 8 (7.5%), 5 (4.7%), 4 (3.7%) and 4 (3.7%) subjects developed a flare-up of plaque, guttate, pustular, erythrodermic, nail and palmoplantar psoriasis.…”